However, the current standard of care using daily dose (2 Gy) fractions of radiation over 6 weeks provides a window of opportunity for a potential daily AMON dosing schedule and sustained MGMT silencing over this time period to enhance the efficacy of CRT in un-methylated for high-grade glioma and potentially other primary brain tumors such as medulloblastoma [2, 43]. The gene discussed is MGMT; the disease is central nervous system cancer.